Breaking News

Merck KGaA, Maker of Erbitux Cancer Drug, to Acquire Sigma-Aldrich for $17 Billion
Tweet TWEET

MELA Sciences, a Leader in the Fight Against Melanoma, Appoints Dr. Darrell Rigel as Chief Medical Advisor to Its Board of

MELA Sciences, a Leader in the Fight Against Melanoma, Appoints Dr. Darrell
Rigel as Chief Medical Advisor to Its Board of Directors

IRVINGTON, N.Y., Oct. 1, 2013 (GLOBE NEWSWIRE) -- MELA Sciences, Inc.
(Nasdaq:MELA), the medical device company that has developed and is
commercializing MelaFind®, the first and only FDA approved optical diagnostic
device for melanoma detection used by dermatologists in their fight against
melanoma, today announced that Darrell S. Rigel, MD MS, Clinical Professor of
Dermatology at New York University, Langone Medical Center, has been appointed
Chief Medical Advisor to the Company's Board of Directors, effective as of
October 1, 2013.

Dr. Rigel, is a Clinical Professor of Dermatology at New York University,
Langone Medical Center and also maintains a private practice in Manhattan, New
York. His clinical interests and expertise include dermatology, melanoma, skin
cancer, photoprotection, and photoaging. In addition to his extensive research
in dermatology, Dr. Rigel has published multiple articles in peer-reviewed
medical journals and is a lead editor of "Cancer of the Skin", one of the most
prominent skin cancer textbooks in the field. He currently serves as a
Regional Chair of the Massachusetts Institute of Technology Educational
Council. He has also served as President of the American Academy of
Dermatology, Director of the American Board of Dermatology, President of the
American Society for Dermatologic Surgery, and President of the American
Dermatological Association.

"We are thrilled to welcome Dr. Rigel as Chief Medical Advisor to the Board of
Directors, and look forward to his contribution to MELA Sciences. His
significant research expertise in skin cancer and dermatology will be
immensely valuable to MELA Sciences as we drive commercial success and
adoption of MelaFind," said Robert Coradini, Interim Chief Executive Officer
of MELA Sciences.

"I am pleased to be joining MELA Sciences as Chief Medical Advisor to the
Board of Directors, and look forward to contributing to the Company's success
and commercial efforts," said Dr. Rigel. "MELA Sciences is emerging as the
leader in the field of diagnostic devices for melanoma detection. Melanoma, if
caught early, is treatable and curable, but continues to lead to a significant
number of unnecessary deaths each year. Along with the team at MELA Sciences,
I am committed to early melanoma detection and saving lives."

Dr. Rigel has presented at over 700 medical and government policy conferences
worldwide and has chaired numerous conferences and symposia. He is the
recipient of several awards and honors including the American Cancer Society's
National Honor Citation for skin cancer programs and Presidential Citations
for public education programs in skin cancer from the American Academy of
Dermatology and American Society for Dermatologic Surgery.

Dr. Rigel received a BS in Management Information Sciences from Massachusetts
Institute of Technology, an MBA from the Sloan School of Management at
Massachusetts Institute of Technology, and a MD from George Washington
University School of Medicine.

About MELA Sciences, Inc.

MELA Sciences is a medical device company focused on the commercialization of
its flagship product, MelaFind® and its further design and development.
MelaFind® is a non-invasive tool to provide additional information to
dermatologists during melanoma skin examinations. The device uses light from
visible to near-infrared wavelengths to evaluate skin lesions up to 2.5 mm
beneath the skin. The device provides information on a lesion's level of
morphologic disorganization to provide additional objective information that
may be used by dermatologists in the biopsy decision-making process. MelaFind®
has been approved by the US Food and Drug Administration for use in the US. In
addition, MelaFind® has received CE Mark approval and is approved for use in
the European Union.

For more information on MELA Sciences, visit www.melasciences.com.

Safe Harbor:

This press release includes "forward-looking statements" within the meaning of
the Securities Litigation Reform Act of 1995. These statements include but are
not limited to our plans, objectives, expectations and intentions and other
statements that contain words such as "expects," "contemplates,"
"anticipates," "plans," "intends," "believes," "assumes," "predicts" and
variations of such words or similar expressions that predict or indicate
future events or trends, or that do not relate to historical matters. These
statements are based on our current beliefs or expectations and are inherently
subject to significant known and unknown uncertainties and changes in
circumstances, many of which are beyond our control. There can be no assurance
that our beliefs or expectations will be achieved. Actual results may differ
materially from our beliefs or expectations due to financial, economic,
business, competitive, market, regulatory and political factors or conditions
affecting the company and the medical device industry in general, as well as
more specific risks and uncertainties facing the company such as those set
forth in its reports on Forms 10-Q and 10-K filed with the U.S. Securities and
Exchange Commission (the "SEC"). Factors that might cause such a difference
include whether MelaFind® achieves market acceptance. Given the uncertainties
affecting companies in the medical device industry such as the Company, any or
all of these forward-looking statements may prove to be incorrect. Therefore,
you should not rely on any such factors or forward-looking statements. The
Company urges you to carefully review and consider the disclosures found in
its filings with the SEC which are available at www.sec.gov and
www.melasciences.com.

CONTACT: For further information contact:
        
         Investors
         Lynn Pieper
         Westwicke Partners
         415-202-5678
        
         Media
         Erica Sperling
         Rpr Marketing Communications
         212-317-1462
         Erica.Sperling@rprmc.com
 
Press spacebar to pause and continue. Press esc to stop.